EPRX
NASDAQ · Biotechnology
Eupraxia Pharmaceuticals Inc
$7.89
+0.09 (+1.15%)
Open$7.81
Previous Close$7.80
Day High$8.13
Day Low$7.81
52W High$12.86
52W Low$5.01
Volume—
Avg Volume50.5K
Market Cap640.25M
P/E Ratio—
EPS$-0.93
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+462.0% upside
Current
$7.89
$7.89
Target
$44.34
$44.34
$25.23
$44.34 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 121.08M | 121.80M | 129.11M |
| Net Income | -20,292,332 | -19,070,968 | -17,081,441 |
| Profit Margin | -16.8% | -15.7% | -13.2% |
| EBITDA | -26,386,283 | -29,891,368 | -27,935,877 |
| Free Cash Flow | -23,062,869 | -20,449,670 | -23,278,243 |
| Rev Growth | +21.7% | +19.1% | -8.5% |
| Debt/Equity | 0.16 | 0.18 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |